secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001437749-26-015352
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q1 revenue $12.5M (+32% YoY); raises FY2026 guidance
-----------------------------------------------------------------

- Total revenue $12.5M, up 32% YoY; Surgical Aesthetics grew 36% to $10.7M.
- Net loss narrowed to $2.1M ($0.05 loss per share) from $4.2M ($0.10 loss).
- Adjusted EBITDA loss improved to $0.3M from $2.4M in prior year.
- Raised FY2026 revenue guidance to $59M-$60M from prior $57.5M-$58.5M.
- International sales strong, especially South Korea; Renuvion won NewBeauty award.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774926015352/0001437749-26-015352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774926015352/apyx20260107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer